Drug Development

Ahead of a critical 2027 data readout, Moleculin pitches a breakthrough leukemia drug while navigating a precarious financial runway.

AmyriAD Therapeutics is betting an all-stock deal can turn a missed Phase 2b endpoint into a breakthrough for cognitive impairment in schizophrenia.

As biopharma pivots to high-dose subcutaneous therapies, conventional delivery systems are hitting a mechanical wall. Early 'systems thinking' is the new mandate.

GC Cell and QuantHealth are deploying predictive AI to simulate clinical trials, aiming to de-risk development and protect capital in cell therapy.

Alpha Cognition is set to present compelling real-world data on ZUNVEYL, revealing how this novel prodrug could reduce psychotropic use in long-term care.

With a newly published pediatric case study and a recent $50 million funding lifeline, Quoin Pharmaceuticals is racing to deliver the first approved therapy for Netherton Syndrome.

Margaret Mitchell explores how a German biotech's moss-grown protein could shift the paradigm in complement-mediated diseases from inhibition to restoration.

With a $50B market in play, NFL Biosciences is leveraging predictive biomarkers and novel neurobiology to disrupt the stagnant smoking cessation landscape.

Vaxcyte is arming itself with $1 billion in fresh capital to challenge Pfizer and Merck, leveraging a dual-tranche financing strategy to scale manufacturing.

Equillium's Phase 1 trial of EQ504 in Australia signals a strategic shift in ulcerative colitis care, prioritizing targeted mucosal healing.

With new Canadian government funding, Vasomune Therapeutics is reformulating its vascular leak drug for the frontlines of military and civilian trauma.

With Phase 3 enrollment complete, vTv Therapeutics aims to succeed where pharmaceutical giants failed in the quest for a Type 1 diabetes pill.

Coave Therapeutics is leveraging AI and novel suprachoroidal delivery to disrupt the wet AMD market, targeting the end of chronic eye injections.

New clinical data published in the Journal of Fungi reveals Moberg Pharma's MOB-015 overcomes terbinafine resistance, unlocking massive market potential.

Antengene’s novel masked CD2 costimulatory platform aims to solve immunotherapy's biggest bottleneck: cytokine toxicity and systemic overheating.

Astellas Pharma's real-world study uses medical-grade wearables to prove its non-hormonal menopause drug Veozah significantly reduces nighttime awakenings.

JCR Pharmaceuticals and Italfarmaco are teaming up to bring a revolutionary, brain-penetrating Hunter syndrome therapy to Western markets.

NORD's latest $145,000 seed funding proves that in the overlooked world of rare diseases, modest philanthropic grants are the ultimate catalyst for innovation.

Biotech challengers are leveraging gene therapy and oral molecules to dismantle the legacy infusion model in the $1.7 billion Fabry disease market.

PolyPid has regained European rights to its promising infection-fighting drug. Now begins a high-stakes race to secure a partner before approval.